Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis

Q Remijisen1,2, V Goossens1,2, S Grootjans1,2, C Van den Haute3, N Vanlangenakker1,2, Y Dondelinger1,2, R Roelant1,2, I Bruggeman1,2, A Goncalves4, MJM Bertrand1,2, V Baekelandt3, N Takahashi1,2, TV Berghe1,2 and P Vandenabeele*,1,2

In human cells, the RIPK1–RIPK3–MLKL–PGAM5–Drp1 axis drives tumor necrosis factor (TNF)-induced necroptosis through mitochondrial fission, but whether this pathway is conserved among mammals is not known. To answer this question, we analyzed the presence and functionality of the reported necroptotic axis in mice. As in humans, knockdown of receptor-interacting kinase-3 (RIPK3) or mixed lineage kinase domain like (MLKL) blocks TNF-induced necroptosis in L929 fibrosarcoma cells. However, repression of either of these proteins did not protect the cells from death, but instead induced a switch from TNF-induced necroptosis to receptor-interacting kinase-1 (RIPK1) kinase-dependent apoptosis. In addition, although mitochondrial fission also occurs during TNF-induced necroptosis in L929 cells, we found that knockdown of phosphoglycerate mutase 5 (PGAM5) and dynamin 1 like protein (Drp1) did not markedly protect the cells from TNF-induced necroptosis. Depletion of Pink1, a reported interactor of both PGAM5 and Drp1, did not affect TNF-induced necroptosis. These results indicate that in these murine cells mitochondrial fission and Pink1 dependent processes, including Pink-Parkin dependent mitophagy, apparently do not promote necroptosis. Our data demonstrate that the core components of the necrosome (RIPK1, RIPK3 and MLKL) are crucial to induce TNF-dependent necroptosis both in human and in mouse cells, but the associated mechanisms may differ between the two species or cell types.

Received 31.10.13; accepted 28.11.13; Edited by G Melino

Necroptosis is a form of regulated necrosis that strictly depends on the kinase activity of receptor-interacting kinase-1 (RIPK1) and receptor-interacting kinase-3 (RIPK3).1 This cell death modality operates independently of executioner caspasases, but is negatively regulated by caspase-8 and therefore is sensitized under conditions of caspase-8 inhibition or deficiency.2 Necroptosis was first observed in L929 murine fibrosarcoma cells as a regulated form of cell death.2 But only with the recent availability of necrostatins3 and RIPK3 knockout mice4 was its importance noted in various pathologies, including ischemia/reperfusion,5,6 inflammatory bowel disease,7,8 viral infection,9 Salmonella infection10 and sepsis.11 The involvement of functional necroptosis in vivo greatly relies on the use of RIPK1 kinase inhibitors such as necrostatin-3,5 and the discovery of RIPK3 as a decisive pro-necroptotic kinase.9,12,13 Members of the tumor necrosis factor (TNF) family are potent inducers of necroptosis. TNF-induced necroptosis involves the formation of a necroosome complex consisting of the core components RIPK1, RIPK3 and mixed lineage kinase domain like (MLKL) that are negatively regulated by factors such as Fas associated death domain protein (FADD), caspase-8 and cellular FLICE inhibitory protein.1,14 Despite the importance of necroptosis, its molecular components and the mechanisms of its regulation and execution remain elusive. Until recently, the only known downstream substrates of RIPK1 and RIPK3 have been RIPKs serving as their own substrates.9 But last year two novel RIPK3 substrates were reported: mixed lineage kinase domain like (MLKL)15,16 and phosphoglycerate mutase 5 (PGAM5).17

MLKL was independently identified by two different groups, who showed that it is constitutively bound by a wild type but not by the kinase-dead RIPK3.15,16 During TNF-induced necroptosis, RIPK3 phosphorylates human MLKL at positions T357 and S358, and these phosphorylations were shown to be essential for TNF-induced necroptosis.15 Although Zhao et al.16 identified MLKL by screening a short hairpin library

1Inflammation Research Center, Molecular Signaling and Cell Death Unit, VIB, Ghent, Belgium; 2Department of Biomedical Molecular Biology, Molecular Signaling and Cell Death Unit, Ghent University, Ghent, Belgium; 3Center for Molecular Medicine, Laboratory for Neurobiology and Gene Therapy, Katholieke Universiteit Leuven, Leuven, Belgium and 4Microscopy Core Facility, Inflammation Research Center, VIB/Ghent University, Ghent, Belgium
*Corresponding author: P Vandenabeele, Department of Biomedical Molecular Biology & Inflammation Research Center, VIB & Ghent University, Technologiepark 927, Zwijnaarde, Ghent B-9052, Belgium. Tel: +32 93313710; Fax: +32 92217673; E-mail: Peter.Vandenabeele@irc.ugent.be

Keywords: RIPK3; MLKL; TNF; apoptosis; necroptosis

Abbreviations: CCCP, carbonyl cyanide m-chlorophenyl hydrzine; cIAP, cellular inhibitor of apoptosis; DEVD-amc, Asp-Glu-Val-Asp-aminoaoycloumarin; Drp1, Dynamin 1 like protein; Mdivi, mitochondrial division inhibitor; MEF, mouse embryonic fibroblast; MLKL, mixed lineage kinase domain like; NSA, necrosulfonamide; PGAM5, phosphoglycerate mutase 5; PINK1, PTEN induced putative kinase-1; RIP, receptor-interacting protein; TMRM, tetramethyl rhodamine methyl ester; TNF, tumor necrosis factor; zVAD-fmk, Z-Val-Ala-Asp-fluoromethylketone

Received 31.10.13; accepted 28.11.13; Edited by G Melino

www.nature.com/cddis

Citation: Cell Death and Disease (2014) 5, e1004; doi:10.1038/cddis.2013.531; published online 16 January 2014

Subject Category: Experimental Medicine
against kinases/phosphatases in HT-29 cells, Sun et al.\textsuperscript{15} identified MLK by screening a large library of compounds against TNF-necroptosis in HT-29 cells and showed that necrosulfonamide (NSA) inhibits TNF-driven necroptosis. Biotinylated NSA was subsequently used to pull down and identify MLK.\textsuperscript{15} Importantly, the Cys86 residue in human MLK – which is targeted by NSA – is absent in murine MLK.\textsuperscript{15} Consequently, NSA does not delay necroptosis in murine cells.\textsuperscript{15}

The second reported RIPK3 substrate is PGAM5.\textsuperscript{17} In humans, the PGAM5 gene encodes two isoforms, PGAM5-L and PGAM5-S, produced by alternative splicing.\textsuperscript{18} PGAM5 constitutively translocates to the mitochondria and has phosphatase activity, but other PGAM members involved in glucose metabolism do not have these properties.\textsuperscript{19} The phosphorylation of PGAM5 during TNF-driven necroptosis has been shown to require RIPK3.\textsuperscript{17} In turn, phosphorylated PGAM5 activates the mitochondrial fission protein, dynamin related kinase-1 (Drp1), by dephosphorylating S637, which then allows Drp1-driven mitochondrial fission.\textsuperscript{17} It has thus been proposed that RIPK3 activates the MLKL–PGAM5–Drp1 axis during necroptosis. The observed mitochondrial fission would thereby serve as a potential execution mechanism during TNF-driven necroptosis.\textsuperscript{17}

In this study, we chose to further examine the contribution of the components of this novel\textsuperscript{17} axis in a prototype murine model of necrosis. We also included Pink1, as this protein is reported to interact with PGAM5\textsuperscript{20} as well as Drp1,\textsuperscript{21} influence cell death\textsuperscript{22} and affect mitochondrial fission.\textsuperscript{23} Pink1 also regulates the removal of damaged mitochondria in a process called mitophagy.\textsuperscript{24} This cellular function requires the E3 ubiquitin ligase Parkin, a downstream regulator of Pink1.\textsuperscript{25} Therefore, we studied a possible contribution of Parkin in TNF-driven necroptosis as well.

Overall, our data show that knockdown of RIPK1, RIPK3 or MLKL strongly attenuates TNF-induced necroptosis in murine cells. In contrast, repression of PGAM5, Pink1 or Parkin has no effect on necroptosis induction, and Drp1 knockdown only mildly delays TNF-induced necroptosis. These data indicate that neither mitochondrial fission nor mitophagy contribute to the execution of TNF-induced necroptosis in our murine cellular system. Of interest, absence of RIPK3 or MLKL not only blocks necroptosis but also shifts the response to RIPK1 kinase-dependent apoptosis.

Results

Knockdown of RIPK3 or MLKL blocks TNF-induced necroptosis and reveals a switch to apoptosis that is dependent on RIPK1 kinase activity. The RIPK1–RIPK3–MLKL–PGAM5–Drp1 axis operates during TNF/zVAD-fmk-induced necroptosis in the presence of SMAC mimetics (SM) in human HT-29 cells and HeLa cells transfected with RIPK3.\textsuperscript{15} It is unknown whether this pathway is conserved among mammalian cells and to which extent it influences induced apoptosis. The murine L929 fibrosarcoma cell line has been the prototype cellular model system for identifying pathways involved in necroptosis.\textsuperscript{2,9,12,13,26,27} It allows TNF-induced necroptosis without the need for adding IAP inhibitors such as SM, or caspase inhibitors such as zVAD-fmk. Therefore, we studied the contribution of the recently identified axis to TNF-induced necroptosis in murine L929 cells. In addition, we also studied its possible contribution to anti-Fas-induced apoptosis. To identify potential cell death modality switches upon interference with either cell death pathway, we simultaneously monitored cell death and caspase activity as a function of time. Knockdown of none of the members of the RIPK1–RIPK3–MLKL–PGAM5–Drp1 axis affected Fas-induced apoptosis, which was visualized by cleavage of a synthetic caspase substrate (Figures 1a and b, right axis) and disruption of the plasma membrane (Figures 1a and b, left axis). As we showed in a previous study,\textsuperscript{14} knockdown of RIPK1 (Figure 1c) did not block TNF-induced cell death but shifted cell death from TNF-induced necroptosis to apoptosis (Figure 1a). Knockdown of MLKL (Figure 1d) significantly delayed TNF-induced necroptosis in L929 cells 6 h after TNF stimulation (Figure 1a), as previously reported for L929 cells.\textsuperscript{15,16} Interestingly, we now show that this delayed cell death is associated with caspase activity (Figures 1a and b), indicating a shift to apoptosis. Apoptosis was confirmed by detecting chromatin condensation and plasma membrane blebbing (Figure 2a). Knockdown of RIPK3 (Figure 1c) completely blocked TNF-induced necroptosis until 6 h after stimulation (Figure 1a). However, cell death observed later was also associated with an increased caspase activity (Figure 1b), indicating a switch to apoptosis as well. Importantly, this TNF-induced apoptosis observed upon knockdown of RIPK3 or MLKL was reduced in the presence of the RIPK1 kinase inhibitor necrostatin-1 (Figure 2b), demonstrating its dependence on the kinase activity of RIPK1.

Evaluation of the possible contribution of the PGAM5–Drp1 axis in TNF-driven necroptosis in L929 cells. Remarkably, and in contrast to TNF-induced necroptosis in HeLa cells transfected with RIPK3,\textsuperscript{17} knockdown of PGAM5 (Figure 1d) did not influence necroptosis in L929 cells (Figures 1a and b and Supplementary Figure S1). Knockdown of the reported PGAM5 target Drp1\textsuperscript{17} was very effective (Figure 1c), but it resulted only in a mild but significant delay of TNF-necroptosis (Figure 1a and Supplementary Figure S1). Note that knockdown of Drp1 markedly slowed down cell proliferation (Figures 3a and b). This was not observed for any other protein examined in this study. We therefore addressed whether the delay in cell proliferation and/or the delay in cell death caused by Drp1 knockdow could be attributed to a decrease in mitochondrial metabolism, which is known to protect from necroptosis.\textsuperscript{13,28,29} However, knockdown of Drp1 did not reduce mitochondrial respiration (Figure 3c), whereas pharmacological inhibition of Drp1 using mitochondrial division inhibitor (mdivi)\textsuperscript{30} did (Figure 4a). The Drp1 inhibitor mdivi markedly delayed TNF-driven necroptosis (Figure 4b), in line with the results obtained in human cells.\textsuperscript{16} The protective effects of mdivi on TNF-induced necroptosis contrast with the mild protection observed after Drp1 knockdown (Figures 1a and b and Supplementary Figure S1). Note that this delay only occurred when mdivi was used at concentrations that also block mitochondrial respiration (Figures 4a and b).
These data suggest that mdivi delays TNF-driven necroptosis because it inhibits mitochondrial respiration rather than mitochondrial fission. In addition, the unaffected mitochondrial respiration upon Drp1 knockdown suggests that mdivi inhibits mitochondrial respiration due to off-target effects independently from targeting Drp1. This illustrates that the effect of mdivi in this context of necroptosis cannot be confined to its inhibitory activity on Drp1. In conclusion, our data
Depletion of RIPK3 or MLKL shifts to apoptosis
Q Remijsen et al

Figure 2 Knockdown of RIPK3 or MLKL results in delayed cell death that switches from TNF-induced necroptosis to a delayed, Nec-1 sensitive apoptosis. (a) Seventy-two hours after knockdown of L929sahFas cells with the indicated siRNAs, cells were pretreated with 10 µM Necrostatin-1 (N1) for 1 h, followed by TNF stimulation (10 000 U/ml) in triplicate. Cell death and caspase activity were determined as described in Materials and Methods. The 12-h time point is shown ± S.E.M (n = 3).

Discussion

We used a murine model of necroptosis to study the contribution of components of the recently identified RIPK1–RIPK3–MLKL–PGAM5–Drp1 axis,17 promoting mitochondrial fission during TNF-induced necroptosis. We also examined whether Pink1, a genetic interactor of PGAM520 and Drp1,21 known to affect mitochondrial fragmentation,23 influences necrotic cell death.

Following TNF stimulation, different types of complexes are formed.23 Complex I mediates NF-κB activation and MAPK signaling, resulting in inflammation and cell survival. The cytotoxic complex II initiates FADD-caspase-8-mediated apoptosis, which under cIAP-depleting conditions can be either independent of the RIPK1 kinase activity (so-called complex Ila) or dependent on it (so-called complex IIb). Typically, RIPK1/3 are inactivated by caspase-8-mediated cleavage, resulting in suppression of necroptosis. When caspase-8 is inhibited or absent, complex II initiates necroptosis, which is dependent on RIPK1–RIPK3–MLKL.15 Uniquely in L929 fibrosarcoma cells, TNF directly induces necroptosis without the need to block caspase-8, which is functionally present.2 We previously have shown that depletion of RIPK1 shifts TNF-induced necroptosis to an accelerated form of apoptosis that is not inhibited by Nec-1 as its target (RIPK1) is depleted.14 These results demonstrate that

demonstrate that knockdown of PGAM5 or Drp1 hardly affects TNF-induced necroptosis in L929 cells. Indeed, kinetics of TNF-necroptosis remain intact upon knockdown of PGAM5 and are mildly delayed upon knockdown of Drp1 (Supplementary Figure S1). It remains possible that the observed delay of cell proliferation upon Drp1 knockdown contributes to this mild protection from TNF-necroptosis.

Evaluation of the possible contribution of the PGAM5–Pink1–Parkin axis in TNF-induced necroptosis. We also examined the possible contribution of Pink1, a genetic interactor of PGAM520 and Drp121 and an upstream regulator of Parkin.25 Transient knockdown of Pink1 markedly delayed TNF-necrosis without a shift toward apoptosis (Figure 1a), whereas stable knockdown of Pink1 did not affect TNF-necroptosis (Supplementary Figure S2). Given these different outcomes, we examined a possible pro-necrotic role of Pink1 using two additional approaches. In the first approach, we found that inducible overexpression of a wild-type Pink1 that is resistant to siRNAs targeting Pink1 could not revert the protective phenotype of siRNAs targeting murine Pink1 (Supplementary Figure S3 and Supplementary Data D1). These data suggest that off-target effects of the siRNAs targeting Pink1 are responsible for their protective effects against TNF-necroptosis. In a second complementary approach, we observed no significant differences in TNF/Tak1/zVAD-fmk-induced cell death between Pink1 KO MEFs and littermate control MEFs (Supplementary Figure S4), indicating that Pink1 has no role in necroptosis.

Finally, we found that knockdown of Parkin (Figure 1c), a downstream effector of Pink1 in the induction of mitophagy, did not affect TNF-necroptosis (Figures 1a and b and Supplementary Figure S1). Because both Pink1 and Parkin did not seem to contribute to TNF-induced necroptosis, we monitored the occurrence of mitophagy, which is preceded by depolarization of mitochondrial membranes. For this purpose, we performed live cell imaging of L929 cells expressing mitochondrially targeted GFP. Within 1–3 h after TNF stimulation, the tubular mitochondrial network of mito-GFP disintegrated in a punctate pattern (Supplementary Figure S5). Importantly, these punctate mito-GFP structures retained their mitochondrial membrane potential, assessed by staining with the mitochondrial potential dye TMRM (Supplementary Figure S5). Consequently, depolarization of mitochondrial membranes, a prerequisite for mitophagy, did not occur during TNF-necroptosis. Altogether, these data argue against the involvement of Pink1–Parkin dependent processes, including mitophagy, in regulating the execution of TNF-necroptosis.
RIPK1 negatively controls FADD-caspase-8-mediated apoptosis. As TRADD and RIPK1 can compete for TNFR-1 binding in complex I, the absence of RIPK1 probably facilitates the interaction of pro-apoptotic proteins, including TRADD, with the TNFR1 and the formation of complex IIa. Here, we show that depletion of RIPK3 or MLKL also shifts TNF-induced necroptosis to apoptosis, albeit with a delay. These results may indicate that RIPK3 and MLKL, like RIPK1, negatively control FADD-caspase-8-mediated apoptosis. Alternatively, RIPK3 and MLKL may just ensure efficient pro-necroptotic signaling, and in their absence apoptosis becomes the default outcome of triggering a cell death pathway. We also observed that the delayed apoptosis upon depletion of RIPK3 or MLKL can be inhibited by Nec-1. RIPK1-kinase-dependent apoptosis was also observed in the presence of IAP inhibitors and TNF, etoposide, TRAIL, or in the presence of Tak1 inhibitor and TNF. These data confirm that RIPK1 kinase activity is involved in both apoptosis and necroptosis. This switch from necroptosis to RIPK1-mediated apoptosis after depletion of RIPK3 and MLKL.
at least in L929 fibrosarcoma cells, should be taken into consideration when developing strategies for interfering with necroptosis induction. Note that the difference in induction rate of apoptosis between RIPK1 and RIPK3/MLKL knockdown may be due to the contribution of RIPK1 within complex I to NF-κB activation, resulting in defective induction of cell death inhibitory proteins such as Bcl-2 members and IAPs, leading to cell death 'without brakes'.

Downstream of the RIPK1–RIPK3–MLKL axis, PGAM5 and Drp1 might function as executioners of necroptosis by activating mitochondrial fission. However, knockdown of PGAM5 did not alter TNF-necroptosis in the murine L929 necroptosis system, in contrast to human cells. Our results are in agreement with the recent report of Murphy et al., who showed that stable knockdown of PGAM5 did not affect TNF-driven necroptosis in both L929 and MEF cells. One possibility is that PGAM5 is a stable protein, and its knockdown at the RNA level does not guarantee the absence of sufficient functional PGAM5 protein. Alternatively, PGAM5 might not regulate TNF-induced necroptosis in murine cells. In this regard, it is noteworthy that PGAM5 exists in two splice variants in human cells, PGAM5-L and PGAM5-S. Knockdown of both variants in human HT-29 cells was recently reported to protect against TNF-induced necroptosis. This protective phenotype could not be reconstituted by reintroduction of PGAM5-L alone, but required reintroduction of PGAM5-S as well. The fact that murine cells express PGAM5-L but not PGAM5-S might explain why a pro-necroptotic role could not be confirmed for PGAM5 in murine cells. In line with this statement is that efficient knockdown of the reported target of PGAM5, namely Drp1, caused only a small delay in TNF-necroptosis. This suggests a minor role for Drp1 and Drp1-mediated processes in TNF-induced necroptosis, such as mitochondrial fragmentation. In apparent contrast with this conclusion is the observation that addition of the Drp1 inhibitor mdivi protects against TNF-necroptosis, in line with a previous report by Wang et al. Overall, we conclude that at least in mouse cells the supposed Drp1 inhibitor mdivi protects from TNF-induced necroptosis by preventing respiration rather than inhibiting Drp1.

Figure 4  The Drp1 inhibitor mdivi inhibits TNF-induced necroptosis and mitochondrial respiration. (a) L929sahFas cells were pretreated with mdivi (0–250 µM) for 1 h and respiration was analyzed as described in Materials and Methods. After four consecutive measurements of basal respiration, the protonophore CCCP was injected (12 µM) and maximal respiration was determined. Rotenone (2.5 µM) and Antimycin-A (5 µM) were then injected to determine the mitochondrial baseline respiration. A representative experiment is shown (n = 2). (b) After pretreatment with mdivi (0–250 µM), L929sahFas cells were stimulated with TNF for 6 h, and cell death was determined by flow cytometry; it is expressed as percentage of SytoxGreen positive cells control ± S.E.M (n = 2). *P < 0.05.
bystander phenomenon than a causal executor of TNF-necroptosis.

Altogether, our data show that not only knockdown of RIPK1, but also of the other two necroosome members RIPK3 and MLKL, blocks necroptosis and shifts the cell death modality to apoptosis, which is dependent on the kinase activity of RIPK1. None of the other supposed downstream necroosome interactors (PGAM5, Drp1) induced this switch, indicating that MLKL is the most downstream effector of necroptosis reported to induce this switch upon knockdown. It is obvious that these switches would be overlooked when studying cellular models of necroptosis that require the use of pan-caspase inhibitors or caspase depletion, as in many studies based on MEF cells. A major advantage of L929 cells is that TNF directly triggers necroptosis in the absence of pan-caspases inhibitors, whereas apoptotic signaling remains possible. We are convinced that the observed switches to apoptosis are of much importance in the search for drugs that are more specific for necroptosis by targeting RIPK3 and/or MLKL. Genetic knockdown and pharmacological inhibition do not always produce the same phenotype, especially when the proteins concerned have platform functions in addition to their enzymatic activities. Nec-1, for example, targets RIPK1 but does not induce a switch from TNF-driven necroptosis to apoptosis. Unfortunately, the recently reported inhibitor of MLKL, NSA, only targets human but not murine MLKL, and so far has been studied only in cellular models of necroptosis requiring caspase inhibition. It therefore remains to be shown in other necroptosis cellular systems, that are independent of caspase inhibitors, whether inhibition of MLKL can rescue cells from death as the cell death signal may switch to RIPK1-mediated apoptosis.

Materials and Methods

Materials. Recombinant human TNF, produced and purified to at least 99% homogeneity in our laboratory, has a specific biological activity of 3 x 10^7 IU/mg. Agonistic anti-human Fas (clone 2R2) was from Cell Diagnostics (Monster, Germany). zVAD-fmk was from Bachem (Bubendorf, Switzerland). Neo-1 was from Calbiochem (San Diego, CA, USA). The Tak1 inhibitor NP-009245 was purchased from AnalytiCon Discovery GmbH (Potsdam, Germany). Ac-DEVD-amc was from PeptivaNova GmbH (Sandhausen, Germany). CCPC, Rotenone and Antimycin-A were purchased from Sigma Aldrich (Steinheim, Germany). NSA was from Toronto Research Chemicals (Toronto, ON, Canada). The Drp1 inhibitor mdivi-1 was from Merck Chemical Ltd (Nottingham, UK). Anti-β-actin (clone C4; MP BiomedicalsEurope NV, Illkirch, France), anti-Parkin (sc-32282) and anti-MLKL (sc-130172) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-RIP1 from BD Biosciences (610459; Franklin Lakes, NJ, USA); and anti-RIP3 (R4277) and anti-MLKL (M6697 and SAB1408429) from Sigma Aldrich. Anti-Drp-1 was from BD Transduction laboratories (clone 8B/DLP1, Franklin Lakes, NJ, USA).

Live cell imaging. Live cell imaging of L929sahFas cells stably expressing mito-GFP was performed on an AS-MDW workstation from Leica (Wetzlar, Germany). One day before imaging, 40,000 cells were seeded in a boricolite eight-chamber plate. Next, the medium was replaced with a medium containing 50 nM TMRM and 50 nM SytoxRed (SR) for 1 h. Cells were then stimulated with TNF and fluorescence (75-W Xenon burner with monochromator set at 2 mW) and DIC images were taken every 5 min. Phototoxicity and photobleaching were prevented by minimizing the exposure time for fluorescence excitation (< 100 ms) and setting the camera at gain 2 and 2 x 2 binning. Different focal planes were set at 1 μm intervals. From each image stack, maximum intensity projections (for SR, mito-GFP and TMRM) were made by using a script developed in-house for ImageJ 1.31i public domain imaging software. The 3D deconvolution (iterative restoration based on calculated PSFs) was performed on Image sequences of mito-GFP and TMRM using the Volocity software 5.2.0. Subsequent montages of the Multi-tiff time series and three-channel overlays were made in ImageJ 1.31i.

Cell culture. L929sahFas cells were generated as previously described. L929sahFas cells with stable knockdown of Pink1 were generated by cloning short hairpins targeted against 3’UTR of Pink1 in GATEWAY compatible pcDNA6.2-GW−: EmGFP-mIR (BLOCK-T Pol II mIR RNAi Expression Vector, Sigma Aldrich), according to the manufacturer’s instructions. Of the 10 sequences targeted in the 3’UTR in Pink1, knockdown was achieved by targeting the 3’UTR sequence cctggagtaggctggcgg (seq 1) and accagagggttgtaagct (seq 2) (Supplementary Data D1). pLenti6 expressing shPink1-EmGFP or mito-GFP was introduced in L929sahFas cells as described previously. All cell lines were cultured in DMEM supplemented with 10% fetal calf serum, penicillin (100 IU/ml), streptomycin (0.1 mg/ml), and L-glutamine (0.03%). Primary, non-immortalized MEFs were isolated and pooled from eight embryos of Pink1 KO mice or control litters, as described previously.

RNAi-mediated knockdown. L929sahFas cells were transfected in six-well plates according to manufacturer’s protocol as described previously. Knockdown was validated by RT-PCR or wherever possible, also by western blotting. Because none of the three antibodies against MLKL could reliably detect MLKL in western blots, we were compelled to validate knockdown of MLKL on the mRNA level. Reliable antibody detection is considered as clear detection of a band of expected molecular weight, of which the intensity can be reduced by knockdown, when knockdown efficiency was already confirmed by qPCR.

Cell death and caspase activity analysis. Cell death was analyzed on a FLUOSTAR Omega (BMG Labtech, Offenburg, Germany). Ten thousand cells were seeded in a transparent 96-well plate. Next day, DMEM was replaced with DMEM containing a 1.6 μM SytoxGreen (SG) and 33 μM Ac-DEVD-amc, and the cells were incubated with various inhibitors for 1 h. Next, cells were stimulated with TNF (10 000 U/ml) or agonistic anti-Fas Ab (250 ng/ml). Maximal cell death was obtained by treatment with Triton-X100 (0.05%). This allows expression of cell death as percent of control of maximal SG fluorescence (excitation 485 nm, emission 520 nm). If executor caspases-3/-7 were activated during cell death, they cleave ac-DEVD-amc only upon plasma membrane rupture. The release of fluorescent 7- amino-4-methylcoumarin (amc) was monitored (excitation 355 nm, emission 460 nm). Alternatively, cell death was analyzed on a BDPathwayTM 855 instrument (BD Biosciences) as described previously and by flow cytometry as previously described.

Mitochondrial respiration. Mitochondrial oxygen consumption in the Leibovitz medium containing 1% FCS was measured in a Seahorse XF96-Analyzer (Seahorse Bioscience, Billerica, MA, USA). Oxygen consumption rates were analyzed following manufacturer’s protocols. Measurements are based on oxygen-dependent quenching of a built-in fluorescent sensor. After four measurements of basal respiration, CCPC was injected (12 μM) and maximal respiration was determined. Rotenone (2.5 μM) and Antimycin-A (5 μM) were then injected to determine the mitochondrial baseline respiration. Subsequently, the amount of cells in the microchamber of each well was determined on a BDPathwayTM 855 instrument as described previously. This allows normalization of the respiratory rates in function to the amount of cells in each microchamber.

Statistics. Using GraphPad Prism Version 6 (San Diego, CA, USA), data were analyzed by one-way ANOVA and a Tukey multiple comparison test, unless indicated otherwise. Statistical significance was accepted at P < 0.05, number of independent experiments are mentioned and all error bars indicate standard error of the mean, unless otherwise indicated.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements.

We thank Amin Bredan for editing the manuscript. PV is senior full professor at Ghent University and holder of a Methusalem grant. TV and QR hold a postdoctoral researcher position with the FWO (Fund for Scientific Research, Flanders). YD is holder of a PhD fellowship from the Agency for
Innovation by Science and Technology. MB has a tenure track position in the Multidisciplinary Research Program of Ghent University. NT, SG and VG are paid from the Methusalem grant. Research in the Vandenberghe group is supported by Belgian grants (Interuniversity Attraction Poles, IAP 7/32), Flemish grants (Research Foundation Flanders – FWO G.0875.11, FWO G.0973.11, FWO G.0.A45.12N, FWO G.0.787.13N Methusalem grant – BOF08/01M00709), Ghent University grants (MRP, GROUP-ID consortium), grant from the Foundation against Cancer, (F94) and grants from the VIB.

1. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700–714.

2. Vermaak D, Beyraut R, Denecker G, Goossens V, Van Loo G, Declercq W et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998; 187: 1477–1485.

3. Degterev A, Hottm J, Germscheid M, Chén IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313–321.

4. Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappa B, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1 and Toll-like receptors 2 and 4. Mol Cell 2004; 24: 1464–1469.

5. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of necroptosis, necrostatin-1, targets RIP1 kinase activity in vivo. J Exp Med 2005; 1: 112–115.

6. Linkermann A, Bräsen J, Himmerkus N, Liu S, Huber T, Kunzendorf U et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 2012; 81: 751–761.

7. Gunther C, Martin E, Wiltkop N, Amann K, Wegmann B, Neumann H et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 325–329.

8. Weis P, Wullaert A, Viantris K, Kondylis V, Fernandez-Majada V, Emoilaeva M et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477: 330–334.

9. Cho YS, Challa S, Moquin D, Deng G, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112–1123.

10. Robinson N, McComb S, Mulligan R, Dudani R, Krishnan L, Sad S. Type I interferon regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 325–329.

11. Lutz A, Exner N, Fett M, Schlehe J, Kloess K, Lämmermann K et al. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem 2009; 284: 22938–22951.

12. Arena G, Gelmetti V, Torsorantucci L, Vignone D, Lamorte G, De Rosa P et al. PINK1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xl and by impairing its pro-apoptotic cleavage. Cell Death Differ 2013; 20: 920–930.

13. Heeman B, Van den Haute C, Aelvoet S-A, Valsecchi F, Rodenburg R, Reuners V et al. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J Cell Sci 2011; 124: 1115–1125.

14. Yeoue R, Narendra D. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12: 9–14.

15. Matsuda N, Sato S, Shiba K, Okatsu K, Saiato K, Sauder K et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. The J Cell Biol 2010; 189: 211–221.

16. Hottm J, Christofferson DE, Ng A, Yao J, Declercq A, Xavier RJ et al. Identification of a molecular signaling network that regulates a necrotic cellular necrosis cell death pathway. Cell 2008; 135: 1311–1323.

17. Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010; 17: 992–1003.

18. Festjens N, Kalai M, Smet J, Meues A, Van Coster R, Saelens X et al. Butylated hydroxyanisole is more than a reactive oxygen species scavenger. Cell Death Differ 2006; 13: 166–169.

19. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens S, Zokey E, Deshayes K et al. siP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2011; 18: 656–665.

20. Casalini-Stone A, Chipuk J, Ingerman E, Song C, You C, Kuwana T et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 2008; 14: 193–204.

21. Declercq W, Vanden Berghe T, Vandenberghe P. RIP kinases at the crossroads of cell death and survival. Cell 2009; 138: 229–232.

22. Pobezeckiykya YL, Kim YS, Choksi S, Morgan MJ, Li T, Liu C et al. The function of TRADD is signaling through tumor necrosis factor receptor 1 and TRAF2-dependent Toll-like receptors. Nat Immunol 2008; 9: 1047–1054.

23. Ermolaeva MA, Mailette MC, Papadopoulou N, Utermohlen O, Kranidioti K, Kollai G et al. Function of TRADD in necrosis is required by receptor 1 signaling and in TRAF-dependent inflammatory responses. Nat Immunol 2008; 9: 1037–1046.

24. Schneider-Brachert W, Tödter V, Heynegier J, Jakob M, Wiktio-Morbach S, Heffeld-Fink J et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF recepetors as death signaling vesicles. Immunity 2004; 21: 415–428.

25. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 349–355.

26. Wang D, Fu D, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693–703.

27. Biton S, Ashkenazi A. NEMO and RIP1 Control Cell Fate in Response to Extensive DNA Damage via TNF-alpha Feedforward Signaling. Cell 2011; 145: 92–103.

28. Tewari T, Bianchi K, Darding M, Broemer M, Langlaas C, Walberg F et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432–448.

29. Feoktistova M, Gesenick P, Kellert B, Dimitrova D, Langlais C, Hupe M et al. dXp1 blocks Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by dFLP isoforms. Mol Cell 2011; 43: 449–463.

30. Dondelinger Y, Aguileta M, Goossens V, Dubuisson C, Grootjans S, Dejardin E et al. Mutant c-IAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 2013; 20: 1381–1392.

31. Murphy J, Czabotar P, Hildebrand J, Lucet I, Zhang J-G, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443–453.

---

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 United States License. To view a copy of this license, view http://creativecommons.org/licenses/by-nc-nd/3.0/